Business

Cyrano Therapeutics has announced a partnership agreement with Chinese CRO Shanghai Newsummit Biopharma (Newsummit) for development of Cyrano’s intranasal theophylline for the treatment of taste and smell disorders in China. Newsummit will provide development services… Read more . . .

Savara has announced that it will develop its Molgradex inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection and plans to initiate a Phase 2a trial for that indication in… Read more . . .

Sunovion has announced the US launch of Seebri Neohaler glycopyrrolate DPI for the treatment of COPD. Seebri Neohaler was approved by the FDA in October 2015. Sunovion acquired US rights to Seebri Neohaler, along with… Read more . . .

Amneal Pharmaceuticals and Impax Laboratories have announced that the companies will merge, with the new company to be called Amneal Pharmaceuticals, Inc. The merger is expected to be complete by mid-2018. OINDPs marketed by Amneal… Read more . . .

Aegis Therapeutics says that it has developed an intranasal hydromorphone for the treatment of acute pain and is making the formulation available for license. According to the company, the formulation, which is based on the… Read more . . .

Engage Therapeutics has closed a $23 million Series A financing round led by TPG Biotech that will fund a Phase 2b clinical trial of an inhaled alprazolam for the treatment of acute epileptic seizures. Alexza… Read more . . .

Galen US has acquired US rights to Alexza Pharmaceuticals’ Adasuve inhaled loxapine for the treatment of agitation in patients with schizophrenia or bipolar I. Adasuve was approved by the FDA in December 2012 for use… Read more . . .

4D Molecular Therapeutics (4DMT) has received $3 million from Cystic Fibrosis Foundation Therapeutics (CFFT) for development of 4D-710, an aerosolized adeno-associated virus (AAV) gene therapy vector that will deliver a functional copy of the CFTR… Read more . . .

The US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded a grant worth up to $63 million to Emergent BioSolutions for development of a single-use stabilized isoamyl nitrite… Read more . . .

Insmed has closed a public offering of common stock that generated net proceeds of ~$377.7 million, the company said. The proceeds will be used in large part for continued development, regulatory submissions, and potential commercialization… Read more . . .